Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:50:45.631Z.
Calculation as of: 2026-10-06T12:50:45.631Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
BlossomHill Therapeutics, Inc.
Market Cap
$579.88M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
EV/Sales Ratio
9.87x
TTM Avg
11.75x
3Y Avg
7.27x
5Y Avg
5.37x
Market Cap
$569.56M
EV/Sales Ratio
0.99x
TTM Avg
2.91x
3Y Avg
806.84x
5Y Avg
1105.61x
Market Cap
$596.36M
EV/Sales Ratio
70.23x
TTM Avg
53.58x
3Y Avg
21.24x
5Y Avg
46.54x
Market Cap
$561.67M
EV/Sales Ratio
30.06x
TTM Avg
14.16x
3Y Avg
5.32x
5Y Avg
4.09x
Market Cap
$547.86M
EV/Sales Ratio
5.27x
TTM Avg
4.75x
3Y Avg
15.43x
5Y Avg
15.84x
Market Cap
$637.59M
EV/Sales Ratio
1.92x
TTM Avg
1.86x
3Y Avg
1.97x
5Y Avg
1.94x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $579.88M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | 9.87x | 11.75x | 7.27x | 5.37x |
| CorMedix Inc. (CRMD)vs › | $569.56M | 0.99x | 2.91x | 806.84x | 1105.61x |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | 70.23x | 53.58x | 21.24x | 46.54x |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | 30.06x | 14.16x | 5.32x | 4.09x |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 5.27x | 4.75x | 15.43x | 15.84x |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | 1.92x | 1.86x | 1.97x | 1.94x |
| Altimmune, Inc. (ALT)vs › | $519.25M | 15869.08x | 12786.98x | 8694.17x | 5938.95x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
